{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T18:58:02Z","timestamp":1794941882675,"version":"4.9.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"8075","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2025,8,7]]},"DOI":"10.1038\/s41586-025-09212-7","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T11:03:06Z","timestamp":1751454186000},"page":"241-251","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery"],"prefix":"10.1038","volume":"644","author":[{"given":"Amanda X. Y.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5009-9895","authenticated-orcid":false,"given":"Kah Min","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9213-6180","authenticated-orcid":false,"given":"Joelle S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4634-7600","authenticated-orcid":false,"given":"Kevin","family":"Sek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2262-7069","authenticated-orcid":false,"given":"Yu-Kuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phoebe A.","family":"Dunbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9429-5254","authenticated-orcid":false,"given":"Volker","family":"Wiebking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse D.","family":"Armitage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6510-5696","authenticated-orcid":false,"given":"Isabelle","family":"Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3903-166X","authenticated-orcid":false,"given":"Kirsten L.","family":"Todd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7191-3948","authenticated-orcid":false,"given":"Emily B.","family":"Derrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dat","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6454-8704","authenticated-orcid":false,"given":"Junming","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheok Weng","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thang X.","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine M.","family":"Audsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9955-6356","authenticated-orcid":false,"given":"Marit J.","family":"van Elsas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4797-9653","authenticated-orcid":false,"given":"Jim","family":"Middelburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel N.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3231-0620","authenticated-orcid":false,"given":"Maria N.","family":"de Menezes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3731-6204","authenticated-orcid":false,"given":"Christina","family":"Scheffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8496-6632","authenticated-orcid":false,"given":"Laura K.","family":"Mackay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4940-0155","authenticated-orcid":false,"given":"Jason","family":"Waithman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2097-6428","authenticated-orcid":false,"given":"Jane","family":"Oliaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4555-6582","authenticated-orcid":false,"given":"Simon J.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3528-478X","authenticated-orcid":false,"given":"Ian A.","family":"Parish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5884-2786","authenticated-orcid":false,"given":"Junyun","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3850-4648","authenticated-orcid":false,"given":"Matthew H.","family":"Porteus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran G.","family":"House","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5303-9561","authenticated-orcid":false,"given":"Phillip K.","family":"Darcy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2116-013X","authenticated-orcid":false,"given":"Paul A.","family":"Beavis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"9212_CR1","doi-asserted-by":"publisher","unstructured":"Albelda, S. M. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat. Rev. Clin. Oncol. https:\/\/doi.org\/10.1038\/s41571-023-00832-4 (2023).","DOI":"10.1038\/s41571-023-00832-4"},{"key":"9212_CR2","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner, R. G. & Mackall, C. L. Clinical lessons learned from the first leg of the CAR T cell journey. Nat. Med. 25, 1341\u20131355 (2019).","journal-title":"Nat. Med."},{"key":"9212_CR3","doi-asserted-by":"publisher","first-page":"eaaw2293","DOI":"10.1126\/scitranslmed.aaw2293","volume":"11","author":"S Mardiana","year":"2019","unstructured":"Mardiana, S., Solomon, B. J., Darcy, P. K. & Beavis, P. A. Supercharging adoptive T cell therapy to overcome solid tumor\u2013induced immunosuppression. Sci. Transl. Med. 11, eaaw2293 (2019).","journal-title":"Sci. Transl. Med."},{"key":"9212_CR4","doi-asserted-by":"publisher","unstructured":"Chmielewski, M. & Abken, H. TRUCKS, the fourth\u2010generation CAR T cells: current developments and clinical translation. Adv. Cell Gene Ther. https:\/\/doi.org\/10.1002\/acg2.84 (2020).","DOI":"10.1002\/acg2.84"},{"key":"9212_CR5","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-14-2085","volume":"21","author":"L Zhang","year":"2015","unstructured":"Zhang, L. et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin. Cancer Res. 21, 2278\u20132288 (2015).","journal-title":"Clin. Cancer Res."},{"key":"9212_CR6","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"9212_CR7","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg6986","volume":"13","author":"Q Zhang","year":"2021","unstructured":"Zhang, Q. et al. A human orthogonal IL-2 and IL-2R\u03b2 system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia. Sci. Transl. Med. 13, eabg6986 (2021).","journal-title":"Sci. Transl. Med."},{"key":"9212_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba1624","volume":"378","author":"GM Allen","year":"2022","unstructured":"Allen, G. M. et al. Synthetic cytokine circuits that drive T cells into immune-excluded tumors. Science 378, eaba1624 (2022).","journal-title":"Science"},{"key":"9212_CR9","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","volume":"119","author":"HJ Pegram","year":"2012","unstructured":"Pegram, H. J. et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119, 4133\u20134141 (2012).","journal-title":"Blood"},{"key":"9212_CR10","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","volume":"71","author":"M Chmielewski","year":"2011","unstructured":"Chmielewski, M., Kopecky, C., Hombach, A. A. & Abken, H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 71, 5697\u20135706 (2011).","journal-title":"Cancer Res."},{"key":"9212_CR11","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","volume":"637","author":"D Steffin","year":"2025","unstructured":"Steffin, D. et al. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature 637, 940\u2013946 (2025).","journal-title":"Nature"},{"key":"9212_CR12","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1016\/j.celrep.2018.04.051","volume":"23","author":"MP Avanzi","year":"2018","unstructured":"Avanzi, M. P. et al. Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system. Cell Rep. 23, 2130\u20132141 (2018).","journal-title":"Cell Rep."},{"key":"9212_CR13","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1016\/j.celrep.2017.11.063","volume":"21","author":"M Chmielewski","year":"2017","unstructured":"Chmielewski, M. & Abken, H. CAR T cells releasing IL-18 convert to T-bethigh FoxO1low effectors that exhibit augmented activity against advanced solid tumors. Cell Rep. 21, 3205\u20133219 (2017).","journal-title":"Cell Rep."},{"key":"9212_CR14","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/s41590-020-0676-7","volume":"21","author":"J Lai","year":"2020","unstructured":"Lai, J. et al. Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity. Nat. Immunol. 21, 914\u2013926 (2020).","journal-title":"Nat. Immunol."},{"key":"9212_CR15","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1016\/j.cell.2023.06.002","volume":"186","author":"L Ma","year":"2023","unstructured":"Ma, L. et al. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell 186, 3148\u20133165 (2023).","journal-title":"Cell"},{"key":"9212_CR16","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","volume":"36","author":"K Adachi","year":"2018","unstructured":"Adachi, K. et al. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat. Biotechnol. 36, 346\u2013351 (2018).","journal-title":"Nat. Biotechnol."},{"key":"9212_CR17","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/mt.2010.313","volume":"19","author":"L Zhang","year":"2011","unstructured":"Zhang, L. et al. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol. Ther. 19, 751\u2013759 (2011).","journal-title":"Mol. Ther."},{"key":"9212_CR18","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","volume":"167","author":"KT Roybal","year":"2016","unstructured":"Roybal, K. T. et al. Engineering T cells with customized therapeutic response programs using synthetic Notch receptors. Cell 167, 419\u2013432 (2016).","journal-title":"Cell"},{"key":"9212_CR19","doi-asserted-by":"publisher","first-page":"eabd8836","DOI":"10.1126\/scitranslmed.abd8836","volume":"13","author":"A Hyrenius-Wittsten","year":"2021","unstructured":"Hyrenius-Wittsten, A. et al. SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. Sci. Transl. Med. 13, eabd8836 (2021).","journal-title":"Sci. Transl. Med."},{"key":"9212_CR20","doi-asserted-by":"publisher","first-page":"1542917","DOI":"10.1080\/2162402X.2018.1542917","volume":"8","author":"A Alsaieedi","year":"2018","unstructured":"Alsaieedi, A., Holler, A., Velica, P., Bendle, G. & Stauss, H. J. Safety and efficacy of Tet-regulated IL-12 expression in cancer-specific T cells. Oncoimmunology 8, 1542917 (2018).","journal-title":"Oncoimmunology"},{"key":"9212_CR21","doi-asserted-by":"publisher","first-page":"e1378842","DOI":"10.1080\/2162402X.2017.1378842","volume":"7","author":"A Kunert","year":"2019","unstructured":"Kunert, A. et al. Intra-tumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors. Oncoimmunology 7, e1378842 (2019).","journal-title":"Oncoimmunology"},{"key":"9212_CR22","doi-asserted-by":"publisher","first-page":"198","DOI":"10.4049\/jimmunol.1800033","volume":"203","author":"Y Liu","year":"2019","unstructured":"Liu, Y. et al. Armored inducible expression of IL-12 enhances antitumor activity of glypican-3\u2013targeted chimeric antigen receptor\u2013engineered T cells in hepatocellular carcinoma. J. Immunol. 203, 198\u2013207 (2019).","journal-title":"J. Immunol."},{"key":"9212_CR23","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem, J. et al. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature 543, 113\u2013117 (2017).","journal-title":"Nature"},{"key":"9212_CR24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s41592-019-0329-7","volume":"16","author":"X Dai","year":"2019","unstructured":"Dai, X. et al. One-step generation of modular CAR-T cells with AAV\u2013Cpf1. Nat. Methods 16, 247\u2013254 (2019).","journal-title":"Nat. Methods"},{"key":"9212_CR25","doi-asserted-by":"publisher","unstructured":"Wiebking, V. et al. Genome editing of donor-derived T-cells to generate allogenic chimeric antigen receptor-modified T cells: optimizing \u03b1\u03b2 T cell-depleted haploidentical hematopoietic stem cell transplantation. Haematologica https:\/\/doi.org\/10.3324\/haematol.2019.233882 (2021).","DOI":"10.3324\/haematol.2019.233882"},{"key":"9212_CR26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1089\/jir.2018.0019","volume":"39","author":"KC Conlon","year":"2019","unstructured":"Conlon, K. C., Miljkovic, M. D. & Waldmann, T. A. Cytokines in the treatment of cancer. J. Interferon Cytokine Res. 39, 6\u201321 (2019).","journal-title":"J. Interferon Cytokine Res."},{"key":"9212_CR27","doi-asserted-by":"publisher","first-page":"a028472","DOI":"10.1101\/cshperspect.a028472","volume":"10","author":"TA Waldmann","year":"2018","unstructured":"Waldmann, T. A. Cytokines in cancer immunotherapy. Cold Spring Harb. Perspect. Biol. 10, a028472 (2018).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"9212_CR28","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aar3451","volume":"3","author":"CJ Kearney","year":"2018","unstructured":"Kearney, C. J. et al. Tumor immune evasion arises through loss of TNF sensitivity. Sci. Immunol. 3, eaar3451 (2018).","journal-title":"Sci. Immunol."},{"key":"9212_CR29","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1158\/0008-5472.CAN-16-1831","volume":"77","author":"S Mardiana","year":"2017","unstructured":"Mardiana, S. et al. A multifunctional role for adjuvant anti-4-1BB therapy in augmenting antitumor response by chimeric antigen receptor T cells. Cancer Res. 77, 1296\u20131309 (2017).","journal-title":"Cancer Res."},{"key":"9212_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.07.018","author":"L Giuffrida","year":"2020","unstructured":"Giuffrida, L. et al. IL-15 preconditioning augments CAR T cell responses to checkpoint blockade for improved treatment of solid tumors. Mol. Ther. https:\/\/doi.org\/10.1016\/j.ymthe.2020.07.018 (2020).","journal-title":"Mol. Ther."},{"key":"9212_CR31","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1158\/1078-0432.CCR-13-0709","volume":"20","author":"JH Sampson","year":"2014","unstructured":"Sampson, J. H. et al. EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin. Cancer Res. 20, 972\u2013984 (2014).","journal-title":"Clin. Cancer Res."},{"key":"9212_CR32","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/00002371-200003000-00001","volume":"23","author":"JC Yang","year":"2000","unstructured":"Yang, J. C. & Perry-Lalley, D. The envelope protein of an endogenous murine retrovirus is a tumor-associated T-cell antigen for multiple murine tumors. J. Immunother. 23, 177\u2013183 (2000).","journal-title":"J. Immunother."},{"key":"9212_CR33","doi-asserted-by":"publisher","first-page":"abe6474","DOI":"10.1126\/science.abe6474","volume":"374","author":"L Zheng","year":"2021","unstructured":"Zheng, L. et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science 374, abe6474 (2021).","journal-title":"Science"},{"key":"9212_CR34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1086\/426833","volume":"76","author":"DA Kleinjan","year":"2005","unstructured":"Kleinjan, D. A. & van Heyningen, V. Long-range control of gene expression: emerging mechanisms and disruption in disease. Am. J. Hum. Genet. 76, 8\u201332 (2005).","journal-title":"Am. J. Hum. Genet."},{"key":"9212_CR35","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41576-019-0128-0","volume":"20","author":"S Schoenfelder","year":"2019","unstructured":"Schoenfelder, S. & Fraser, P. Long-range enhancer\u2013promoter contacts in gene expression control. Nat. Rev. Genet. 20, 437\u2013455 (2019).","journal-title":"Nat. Rev. Genet."},{"key":"9212_CR36","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.omto.2018.11.003","volume":"12","author":"R Uchibori","year":"2019","unstructured":"Uchibori, R. et al. Functional analysis of an inducible promoter driven by activation signals from a chimeric antigen receptor. Mol. Ther. Oncolytics 12, 16\u201325 (2019).","journal-title":"Mol. Ther. Oncolytics"},{"key":"9212_CR37","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1021\/acssynbio.1c00236","volume":"11","author":"T Guo","year":"2022","unstructured":"Guo, T., Ma, D. & Lu, T. K. Sense-and-respond payload delivery using a novel antigen-inducible promoter improves suboptimal CAR-T activation. ACS Synth. Biol. 11, 1440\u20131453 (2022).","journal-title":"ACS Synth. Biol."},{"key":"9212_CR38","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","volume":"567","author":"J Chen","year":"2019","unstructured":"Chen, J. et al. NR4A transcription factors limit CAR T cell function in solid tumours. Nature 567, 530\u2013534 (2019).","journal-title":"Nature"},{"key":"9212_CR39","doi-asserted-by":"publisher","first-page":"12410","DOI":"10.1073\/pnas.1905675116","volume":"116","author":"H Seo","year":"2019","unstructured":"Seo, H. et al. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion. Proc. Natl Acad. Sci. USA 116, 12410\u201312415 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"9212_CR40","doi-asserted-by":"publisher","first-page":"eabh1873","DOI":"10.1126\/sciimmunol.abh1873","volume":"7","author":"N Weisshaar","year":"2022","unstructured":"Weisshaar, N. et al. Rgs16 promotes antitumor CD8+ T cell exhaustion. Sci. Immunol. 7, eabh1873 (2022).","journal-title":"Sci. Immunol."},{"key":"9212_CR41","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41591-020-0840-5","volume":"26","author":"Y Lu","year":"2020","unstructured":"Lu, Y. et al. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. Nat. Med. 26, 732\u2013740 (2020).","journal-title":"Nat. Med."},{"key":"9212_CR42","doi-asserted-by":"publisher","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","volume":"367","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer, E. A. et al. CRISPR-engineered T cells in patients with refractory cancer. Science 367, eaba7365 (2020).","journal-title":"Science"},{"key":"9212_CR43","doi-asserted-by":"publisher","first-page":"6709","DOI":"10.1158\/1078-0432.CCR-09-0536","volume":"15","author":"RA Herbertson","year":"2009","unstructured":"Herbertson, R. A. et al. Phase I biodistribution and pharmacokinetic study of Lewis Y\u2013targeting Immunoconjugate CMD-193 in patients with advanced epithelial cancers. Clin. Cancer Res. 15, 6709\u20136715 (2009).","journal-title":"Clin. Cancer Res."},{"key":"9212_CR44","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1158\/1078-0432.CCR-07-0284","volume":"13","author":"AM Scott","year":"2007","unstructured":"Scott, A. M. et al. A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen. Clin. Cancer Res. 13, 3286\u20133292 (2007).","journal-title":"Clin. Cancer Res."},{"key":"9212_CR45","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1038\/mt.2013.154","volume":"21","author":"DS Ritchie","year":"2013","unstructured":"Ritchie, D. S. et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol. Ther. 21, 2122\u20132129 (2013).","journal-title":"Mol. Ther."},{"key":"9212_CR46","doi-asserted-by":"publisher","first-page":"9578484","DOI":"10.1155\/2020\/9578484","volume":"2020","author":"H-T Wu","year":"2020","unstructured":"Wu, H.-T. et al. The tumor suppressive roles and prognostic values of STEAP family members in breast cancer. BioMed. Res. Int. 2020, 9578484 (2020).","journal-title":"BioMed. Res. Int."},{"key":"9212_CR47","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1080\/15384047.2019.1685290","volume":"21","author":"Q Yang","year":"2020","unstructured":"Yang, Q., Ji, G. & Li, J. STEAP2 is down-regulated in breast cancer tissue and suppresses PI3K\/AKT signaling and breast cancer cell invasion in vitro and in vivo. Cancer Biol. Ther. 21, 278\u2013291 (2020).","journal-title":"Cancer Biol. Ther."},{"key":"9212_CR48","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1016\/j.ajpath.2018.05.014","volume":"188","author":"KL Moek","year":"2018","unstructured":"Moek, K. L., Fehrmann, R. S. N., van der Vegt, B., de Vries, E. G. E. & de Groot, D. J. A. Glypican 3 overexpression across a broad spectrum of tumor types discovered with functional genomic mRNA profiling of a large cancer database. Am. J. Pathol. 188, 1973\u20131981 (2018).","journal-title":"Am. J. Pathol."},{"key":"9212_CR49","doi-asserted-by":"publisher","unstructured":"Sek, K. et al. Tumor site-directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors. Nat. Commun. https:\/\/doi.org\/10.1038\/s41467-025-59021-9 (2025).","DOI":"10.1038\/s41467-025-59021-9"},{"key":"9212_CR50","doi-asserted-by":"publisher","first-page":"9591","DOI":"10.1158\/0008-5472.CAN-10-2884","volume":"70","author":"LXJ Wang","year":"2010","unstructured":"Wang, L. X. J. et al. Tumor ablation by gene-modified T cells in the absence of autoimmunity. Cancer Res. 70, 9591\u20139598 (2010).","journal-title":"Cancer Res."},{"key":"9212_CR51","doi-asserted-by":"publisher","first-page":"5787","DOI":"10.4049\/jimmunol.171.11.5787","volume":"171","author":"MP Piechocki","year":"2003","unstructured":"Piechocki, M. P., Ho, Y.-S., Pilon, S. & Wei, W.-Z. Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines. J. Immunol. 171, 5787\u20135794 (2003).","journal-title":"J. Immunol."},{"key":"9212_CR52","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1089\/153685903322328947","volume":"22","author":"Z Liu","year":"2003","unstructured":"Liu, Z. et al. Generation of anti-idiotype antibodies for application in clinical immunotherapy laboratory analyses. Hybrid. Hybridomics 22, 219\u2013228 (2003).","journal-title":"Hybrid. Hybridomics"},{"key":"9212_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23331-5","volume":"12","author":"L Giuffrida","year":"2021","unstructured":"Giuffrida, L. et al. CRISPR\/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy. Nat. Commun. 12, 3236 (2021).","journal-title":"Nat. Commun."},{"key":"9212_CR54","doi-asserted-by":"publisher","first-page":"182","DOI":"10.4049\/jimmunol.166.1.182","volume":"166","author":"NM Haynes","year":"2001","unstructured":"Haynes, N. M. et al. Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-\u03b6 vs Fc\u03b5RI-\u03b3. J. Immunol. 166, 182\u2013187 (2001).","journal-title":"J. Immunol."},{"key":"9212_CR55","doi-asserted-by":"publisher","first-page":"5636","DOI":"10.1158\/1078-0432.CCR-13-0458","volume":"19","author":"LB John","year":"2013","unstructured":"John, L. B. et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin. Cancer Res. 19, 5636\u20135646 (2013).","journal-title":"Clin. Cancer Res."},{"key":"9212_CR56","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3390\/cancers12020375","volume":"12","author":"K Zimmermann","year":"2020","unstructured":"Zimmermann, K. et al. Design and characterization of an \u201call-in-one\u201d lentiviral vector system combining constitutive anti-GD2 CAR expression and inducible cytokines. Cancers 12, 375 (2020).","journal-title":"Cancers"},{"key":"9212_CR57","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/bioinformatics\/bts196","volume":"28","author":"DS DeLuca","year":"2012","unstructured":"DeLuca, D. S. et al. RNA-SeQC: RNA-seq metrics for quality control and process optimization. Bioinformatics 28, 1530\u20131532 (2012).","journal-title":"Bioinformatics"},{"key":"9212_CR58","doi-asserted-by":"publisher","first-page":"D754","DOI":"10.1093\/nar\/gkx1098","volume":"46","author":"DR Zerbino","year":"2018","unstructured":"Zerbino, D. R. et al. Ensembl 2018. Nucleic Acids Res. 46, D754\u2013D761 (2018).","journal-title":"Nucleic Acids Res."},{"key":"9212_CR59","doi-asserted-by":"publisher","first-page":"4288","DOI":"10.1093\/nar\/gks042","volume":"40","author":"DJ McCarthy","year":"2012","unstructured":"McCarthy, D. J., Chen, Y. & Smyth, G. K. Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res. 40, 4288\u20134297 (2012).","journal-title":"Nucleic Acids Res."},{"key":"9212_CR60","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2010).","journal-title":"Bioinformatics"},{"key":"9212_CR61","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289\u20131296 (2019).","journal-title":"Nat. Methods"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09212-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09212-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09212-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:13:10Z","timestamp":1757203990000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09212-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":61,"journal-issue":{"issue":"8075","published-print":{"date-parts":[[2025,8,7]]}},"alternative-id":["9212"],"URL":"https:\/\/doi.org\/10.1038\/s41586-025-09212-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3752711\/v1","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"14 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.A.B. declares research funding from Bristol-Myers-Squibb. P.K.D. declares research funding from Myeloid Therapeutics, Prescient Therapeutics, Bristol-Myers-Squibb and Juno Therapeutics. I.A.P. declares research funding from AstraZeneca, Bristol-Myers-Squibb and Roche Genentech. The authors declare the following patents related to this work: PCT\/AU2021\/051219, \u2018Composition and methods for immunotherapy\u2019 (19 October 2021) (A.X.Y.C., I.G.H., P.K.D. and P.A.B.); and PCT\/AU2024\/050379, \u2018Compositions & methods for immunotherapy \u2013 II\u2019 (20 April 2023)\u00a0(A.X.Y.C., K.M.Y., P.K.D. and P.A.B).\u00a0M.H.P. serves on the Scientific Advisory Board of Allogene Therapeutics\u00a0and Biogen. He is on the Board of Directors and has equity in Kamau Therapeutics\u00a0and has equity in CRISPR Therapeutics. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}